Diligence memo · auto-generated · as of July 2, 2026
EnzymeBioSystems
EnzymeBioSystems looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
EnzymeBioSystems operates in Pharmaceuticals, based in LAS VEGAS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
EnzymeBioSystems has raised $390K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $390K on 2017-09-06.
Most recent recorded round closed around 2017-09-06.
Valuation (modeled)modeled
Provath models EnzymeBioSystems at approximately $18M (range $218K–$209M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.97× the median modeled value of Pre-Seed Pharmaceuticals companies in 2016–2018 (56 peers) — value vs value, same stage and era. Within the normal band (97% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 8.8 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 10% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 26% of those peers.
Closest niche peers: Essentia Pharma Socal, Llc, Essentia Pharma Florida, Llc, Novellus LLC, Blake Insomnia Therapeutics, Inc., Eleusis Benefit Corporation, PBC.
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.